A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced H...
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma
About this item
Full title
Author / Creator
Sho, Takuya , Nakanishi, Mitsuru , Morikawa, Kenichi , Ohara, Masatsugu , Kawagishi, Naoki , Izumi, Takaaki , Umemura, Machiko , Ito, Jun , Nakai, Masato , Suda, Goki , Ogawa, Koji , Chuma, Makoto , Meguro, Takashi , Nakamura, Michio , Nagasaka, Atsushi , Horimoto, Hiromasa , Yamamoto, Yoshiya and Sakamoto, Naoya
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Background and aims
Sorafenib is the first molecular targeted drug approved for the treatment of advanced hepatocellular carcinoma (HCC) and is a potent small molecule inhibitor of multiple kinases. Combination therapy with sorafenib and other cytotoxic agents for HCC may result in additive anticancer activity. The purpose of this phase I study...
Alternative Titles
Full title
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5629128
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5629128
Other Identifiers
ISSN
1174-5886
E-ISSN
1179-6901
DOI
10.1007/s40268-017-0187-7
